Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
In conclusion, pazopanib was safe and effective to manage severe bleeding in HHT, liberating all patient s from transfusion dependence and normalizing hematologic parameters at doses lower than used to treat malignancies. These findings require confirmation in a randomized trial.
Source: Angiogenesis - Category: Molecular Biology Source Type: research
More News: Anemia | Bleeding | Cancer & Oncology | Epistaxis (Nosebleeds) | Gastroenterology | Hematology | Hereditary Hemorrhagic Telangiectasia | Hypertension | Iron | Molecular Biology